Forte Biosciences (FBRX) Shares Outstanding (Weighted Average) (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $4.0 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $4.0 million, down 17.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (down 17.86% YoY), and the FY2025 annual result was $4.9 million, down 2.41% from the prior year.
• Shares Outstanding (Weighted Average) declined to $4.0 million in Q1 2026 per FBRX's latest filing, from $4.9 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $21.0 million in Q2 2023 and troughed at $387566.0 in Q3 2024.
• A 5-year average of $9.7 million and a median of $9.7 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) tumbled 91.02% in 2023, then soared 1268.67% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $17.4 million in 2022, then sank by 44.26% to $9.7 million in 2023, then slumped by 48.36% to $5.0 million in 2024, then slipped by 2.41% to $4.9 million in 2025, then declined by 18.96% to $4.0 million in 2026.
• Business Quant data shows FBRX's Shares Outstanding (Weighted Average) at $4.0 million in Q1 2026, $4.9 million in Q4 2025, and $5.3 million in Q3 2025.